NL-OMON28322尚未招募不适用
Vitamin K antagonists (VKA) versus New Oral Anticoagulants (NOACs) in patients with currently well controlled VKA therapy for non-valvular atrial fibrillation: a pilot study.
niversity Medical Centre Groningen0 个研究点目标入组 240 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Men or women aged >= 18 years who are currently treated with VKA for non-valvular atrial fibrillation, managed by the Groningen Thrombosis Service.
- •-A minimum duration of 6 months of VKA treatment at the time of selection by the Thrombosis Service.
排除标准
- •-A thrombo-embolic event or major bleeding ever while on VKA.
- •-Indication for anticoagulation other than atrial fibrillation.
研究者
相似试验
进行中（未招募）
1 期
Research on anticoagulant treatment in atrial fibrillatioEUCTR2013-004805-14-NLniversity Medical Center Groningen241
已完成
4 期
Vitamin K antagonist (VKA) therapy versus New Oral Anticoagulants (NOACs) therapy in patients with currently well controlled VKA therapy for non-valvular atrial fibrillation: a pilot studyatrial fibrillationcardiac arrhythmiaNL-OMON41389niversitair Medisch Centrum Groningen240
已完成
不适用
Prospective study of non-vitamin K antagonist oral anticoagulants (NOACs) management in Japanese patients with deep vein thrombosis and pulmonary embolism (DVT/PE)Venous thrombosisJPRN-UMIN000023747Department of Cardiology and Nephrology, Mie University Graduate School of Medicine1,000
进行中（未招募）
1 期
The Direct Oral Anticoagulation versus Vitamin K Antagonist after Cardiac Surgery (DANCE) TrialPatients with atrial fibrillation requiring anticoagulation.MedDRA version: 20.0Level: PTClassification code: 10003658Term: Atrial fibrillation Class: 100000004849CTIS2023-504504-28-00Hamilton Health Sciences Corporation6,215
尚未招募
不适用
efficacy and safety of non vitamin K anticoagulants compared to vitamin K anticoagulants in treatment of atrial fibrillation patientsCTRI/2022/05/042669srm college of pharmacy